JAKKS Pacific - JAKK Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for JAKKS Pacific in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JAKK shares.
View JAKK analyst ratings or view top-rated stocks.

2 analysts have issued 12 month price targets for JAKKS Pacific's shares. Their JAKK share price forecasts range from $21.00 to $30.00. On average, they expect the company's stock price to reach $24.67 in the next twelve months. This suggests a possible upside of 69.4% from the stock's current price.
View analysts price targets for JAKK or view top-rated stocks among Wall Street analysts.

JAKKS Pacific's stock was trading at $17.49 at the beginning of 2023. Since then, JAKK stock has decreased by 16.8% and is now trading at $14.56.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our JAKK earnings forecast.

JAKKS Pacific, Inc. (NASDAQ:JAKK) released its earnings results on Wednesday, October, 27th. The company reported $3.76 EPS for the quarter, beating analysts' consensus estimates of $3.36 by $0.40. The business earned $236.96 million during the quarter, compared to the consensus estimate of $262.30 million. JAKKS Pacific had a trailing twelve-month return on equity of 40.26% and a net margin of 11.51%. During the same quarter in the previous year, the company posted $4.76 EPS.

First Trust Dow Jones Select Microcap Index Fund holds 17,002 shares of JAKK stock, representing 0.22% of its portfolio.

55 employees have rated JAKKS Pacific Chief Executive Officer Stephen G. Berman on Glassdoor.com. Stephen G. Berman has an approval rating of 59% among the company's employees. This puts Stephen G. Berman in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other JAKKS Pacific investors own include KKR & Co. Inc. (KKR), Rockwell Medical (RMTI), Inovio Pharmaceuticals (INO), OpGen (OPGN), Vaxart (VXRT), Groupon (GRPN), iBio (IBIO), J C Penney (JCP), Kinross Gold (KGC) and SMTC (SMTX).

JAKKS Pacific trades on the NASDAQ under the ticker symbol "JAKK."

JAKKS Pacific's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Morgan Stanley (3.10%), Renaissance Technologies LLC (2.87%), Millennium Management LLC (1.68%), Marshall Wace LLP (1.46%), Two Sigma Investments LP (1.34%) and Geode Capital Management LLC (0.77%). Insiders that own company stock include Benefit Street Partners Llc, Lawrence I Rosen and Stephen G Berman.
View institutional ownership trends.

Shares of JAKK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of JAKK stock can currently be purchased for approximately $14.56.

JAKKS Pacific (NASDAQ:JAKK) has a market capitalization of $141.52 million and generates $796.19 million in revenue each year. The company earns $92.70 million in net income (profit) each year or $8.93 on an earnings per share basis.

The company employs 583 workers across the globe.

JAKKS Pacific's mailing address is 2951 28TH STREET, SANTA MONICA CA, 90405. The official website for the company is www.jakks.com. The company can be reached via phone at (424) 268-9444, via email at investor.relations@jackinthebox.com, or via fax at 310-317-8527.